Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children.
Eighty-one children seronegative for markers of hepatitis B virus infection aged 0-10 years received 10 micrograms of a yeast-based hepatitis B vaccine (Engerix B) at 0, 1, and 6 months. Eighty subjects responded with a geometric mean titre of 7640 IU/L one month after the third dose. All seroconverters produced high level of antibodies regardless of age, race, or sex. It is concluded that Engerix B used in the dose and schedule described is highly immunogenic.
Moyes
C
C
Hepatitis B Research Unit, Whakatane Hospital.
Milne
A
A
D000941:Antigens / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D017325:Hepatitis B Vaccines; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008297:Male; D011863:Radioimmunoassay; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology*; D014761:Viral Hepatitis Vaccines / Q000009:adverse effects / Q000276:immunology*
D000941:Antigens; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines